New herpes drug shows promise in early safety trial

NCT ID NCT06385327

First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-stage study tested a new drug called ABI-5366 in 115 people to see if it is safe and how the body processes it. The trial included healthy volunteers and people with recurrent genital herpes caused by HSV-2. The goal was to gather safety data and understand dosing, not to prove the drug works yet.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GENITAL HERPES SIMPLEX TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Canopy Beaches Clinical Research

    Sydney, New South Wales, 2100, Australia

  • Canopy Clinical Sutherland

    Miranda, New South Wales, 2228, Australia

  • Canopy Clinical Wollongong

    Wollongong, New South Wales, 2500, Australia

  • East Sydney Doctors

    Darlinghurst, New South Wales, 2010, Australia

  • Momentum Clinical Research

    Sydney, New South Wales, 2010, Australia

  • Momentum Kapiti

    Waikanae, 5036, New Zealand

  • Momentum Palmerston North

    Palmerston North, 4414, New Zealand

  • Momentum Sunshine

    Melbourne, Victoria, 3021, Australia

  • New Zealand Clinical Research

    Auckland, 1010, New Zealand

  • New Zealand Clinical Research Christchurch

    Christchurch, 8011, New Zealand

  • Pacific Clinical Research Network - Hamilton

    Hamilton, 3200, New Zealand

  • Pacific Clinical Research Network - Rotorua

    Rotorua, 3010, New Zealand

  • Pacific Clinical Research Network - Tasman

    Nelson, 7011, New Zealand

  • Pacific Clinical Research Network - Wellington

    Upper Hutt, 5018, New Zealand

  • Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

Conditions

Explore the condition pages connected to this study.